Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT).

被引：0
|
作者：
Tahara, Makoto
Schlumberger, Martin
Elisei, Rossella
Habra, Mouhammed Amir
Kiyota, Naomi
Dutcus, Corina
Xu, Jianbo
Zhu, Junming
Hihara, Taro
McGrath, Shannon
Matijevic, Mark
Kadowaki, Tadashi
Funahashi, Yasuhiro
Sherman, Steven I.
机构：
[1] Natl Canc Ctr Hosp East, Dept Head & Neck Med Oncol, Kashiwa, Chiba, Japan
[2] Gustave Roussy, Dept Nucl Med & Endocrine Oncol, Villejuif, France
[3] Univ Paris 11, Villejuif, France
[4] Univ Pisa, Dept Endocrinol, Pisa, Italy
[5] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Div Internal Med, Houston, TX 77030 USA
[6] Kobe Univ Hosp, Dept Med, Div Med Oncol Hematol, Kobe, Hyogo, Japan
[7] Grad Sch Med, Kobe, Hyogo, Japan
[8] Eisai Inc, Woodcliff Lake, NJ USA
[9] Eisai & Co Ltd, Tsukuba, Ibaraki, Japan
[10] Eisai Inc, Andover, MA USA
[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.6014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6014
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Baseline characteristics of responders and nonresponders from the phase 3 study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT)
    Reuter, C.
    Yu, X.
    Baig, M.
    Dutcus, C. E.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S112 - S113
  • [22] A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with I-refractory differentiated thyroid cancer (SELECT)
    Schlumberger, M.
    Tahara, M.
    Wirth, L.
    Robinson, B.
    Brose, M.
    Elisei, R.
    Dutcus, C.
    de las Heras, B.
    Zhu, J.
    Habra, M.
    Newbold, K.
    Shah, M. H.
    Hoff, A. O.
    Gianoukakis, A. G.
    Kiyota, N.
    Taylor, M.
    Kim, S-B
    Krzyzanowska, M.
    Sherman, S., I
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 119 - 119
  • [23] Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine- refractory differentiated thyroid cancer
    Tahara, Makoto
    Brose, Marcia S.
    Wirth, Lori J.
    Suzuki, Takuya
    Miyagishi, Hideaki
    Fujino, Katsuki
    Dutcus, Corina E.
    Gianoukakis, Andrew
    EUROPEAN JOURNAL OF CANCER, 2019, 106 : 61 - 68
  • [24] THE EFFECT OF LENVATINIB AND PEMBROLIZUMAB ON THYROID CANCER REFRACTORY TO IODINE 131I SIMULATED BY MATHEMATICAL MODELING
    Da Silva, Jairo Gomes
    Rodrigues Da Silva, Izabel Cristina
    Adimy, Mostafa
    De Arruda Mancera, Paulo Fernando
    JOURNAL OF BIOLOGICAL SYSTEMS, 2022, 30 (01) : 93 - 112
  • [25] Impact of Duration of Dose Interruption on the Efficacy of Lenvatinib (LEN) in A Phase III Study in Patients (pts) With Radioiodine Refractory Differentiated Thyroid Cancer (RR-DTC)
    Tahara, Makoto
    Brose, Marcia
    Wirth, Lori
    Suzuki, Takuya
    Fujino, Katsuki
    Batty, Nicolas
    Dutcus, Corina
    Young, Louise
    Gianoukakis, Andrew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 139 - 140
  • [26] A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 134I-refractory differentiated thyroid cancer (SELECT)
    Schlumberger, Martin
    Tahara, Makoto
    Wirth, Lori J.
    Robinson, Bruce
    Brose, Marcia S.
    Ellsel, Rossella
    Dutcus, Corina E.
    de las Hares, Begona
    Zhu, Junming
    Habra, Mouhamed Amir
    Newbold, Kate
    Shah, Manisha H.
    Hoff, Ana O.
    Gianoukakis, Andrew G.
    Kiyota, Naomi
    Taylor, Matthew Hiram
    Kim, Sung-Bae
    Krzyranowska, Monika K.
    Sherman, Steven I.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial
    Kiyota, Naomi
    Tahara, Makoto
    Robinson, Bruce
    Schlumberger, Martin
    Sherman, Steven, I
    Leboulleux, Sophie
    Lee, Eun Kyung
    Suzuki, Takuya
    Ren, Min
    Fushimi, Kazuma
    Wirth, Lori J.
    CANCER, 2022, 128 (12) : 2281 - 2287
  • [28] Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea
    Song, Eyun
    Kim, Mijin
    Kim, Eui Young
    Kim, Bo Hyun
    Shin, Dong Yeob
    Kang, Ho-Cheol
    Ahn, Byeong-Cheol
    Kim, Won Bae
    Shong, Young Kee
    Jeon, Min Ji
    Lim, Dong Jun
    THYROID, 2020, 30 (05) : 732 - 738
  • [29] Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial
    Brose, Marcia S.
    Schlumbeger, Martin
    Jeffers, Michael
    Kappeler, Christian
    Meinhardt, Gerold
    Pena, Carol E. A.
    CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7370 - 7380
  • [30] Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
    Finn, Richard S.
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Wyrwicz, Lucjan
    Ngan, Roger K. C.
    Blanc, Jean-Frederic
    Baron, Ari D.
    Vogel, Arndt
    Ikeda, Masafumi
    Piscaglia, Fabio
    Han, Kwang-Hyub
    Qin, Shukui
    Minoshima, Yukinori
    Kanekiyo, Michio
    Ren, Min
    Dairiki, Ryo
    Tamai, Toshiyuki
    Dutcus, Corina E.
    Ikezawa, Hiroki
    Funahashi, Yasuhiro
    Evans, Thomas R. Jeffry
    CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4848 - 4858
12345